法国Nanobiotix  
Nanobiotix是一家纳米医药公司，总部在法国巴黎，致力于开发抗癌新药。公司整合了纳米科技与生物技术的优势。Nanobiotix衍生于布法罗的纽约州立大学，成立于2003年。其资金来源于几家领先的欧洲风投公司（Matignon Investissement & Gestion、OTC Asset Management、Cap Decisif Management、Amorcage Rhone-Alpes、CM-CIC Capital Innovation和Masseran Gestion）。Nanobiotix已开发出若干种新化合物，其目标是提升自身在纳米医药领域的领先地位。

Nanobiotix is a nanomedicine company that intends to revolutionize cancer treatment. Nanobiotix is focused on the development of NanoXray, its innovative pipeline based on a physical mechanism of action with deposit of high quantity of energy within the tumor cells. Nanobiotix is committed to provide patients with meaningful local cancer treatment.

NanoXray products interact with radiotherapy improving the tumor control using the existing standard radiation equipment available in almost every hospital world-wide. Radiation is a standard therapy used in the treatment of approximately 60% of cancer patients.

Nanobiotix is based in Paris, France. Nanobiotix is a spin-off of the State University of New York (SUNY) at Buffalo that was incorporated in 2003 and has been primarily funded by leading European venture capital firms (Matignon Technologies, OTC Asset Management, Cap Decisif, Amorcage Rhone-Alpes, CM-CIC Capital Innovation, Masseran Gestion-CGE). Today, the company has more than 30 employees and has received total funding to date more than € 26 million.

With the development of numerous new compounds, Nanobiotix’s objective is to increase its leading position in nanomedicine field. A major milestone and validation of Nanobiotix approach is its First-in-Human clinical study of NanoXray therapeutics for refractory solid tumors in 2011.